deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02184195

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Sponsor: AstraZeneca

Conditions Germline BRCA1/2 Mutations and Metastatic Adenocarcinoma of the Pancreas
Interventions Olaparib Placebo
Updated 35 times since 2017 Last updated: Aug 18, 2023 Started: Dec 16, 2014 Primary completion: Jan 15, 2019 Completion: Jan 27, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Germline BRCA1/2 Mutations and and Metastatic Adenocarcinoma of the Pancreas and is currently completed. AstraZeneca leads this study, which shows 35 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

35 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Mar 2023 — Oct 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 30 earlier versions

  1. Nov 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Oct 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  7. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  9. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  10. Aug 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Apr 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  13. Feb 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  14. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  15. Sep 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  16. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  17. May 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  18. Feb 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  19. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  20. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  21. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  22. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  23. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  24. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  25. Dec 2017 — Apr 2018 [monthly]

    Recruiting PHASE3

  26. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  27. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  28. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  29. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE3

  30. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Merck Sharp & Dohme LLC
  • Myriad Genetic Laboratories, Inc.
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Amsterdam, Netherlands , Antwerp, Belgium , Aurora, United States , Baltimore, United States , Barcelona, Spain , Beersheba, Israel , Berlin, Germany , Besançon, France , Boca Raton, United States and 80 more locations